Browse Category

Pharmaceuticals News 22 July 2025

Revolutionary Medical Breakthroughs of July 2025: Life-Changing Drugs, Diagnostic Wonders & Public Health Milestones

Revolutionary Medical Breakthroughs of July 2025: Life-Changing Drugs, Diagnostic Wonders & Public Health Milestones

On July 2, 2025, the FDA granted accelerated approval to linvoseltamab (Lynozyfic), a BCMA-targeting bispecific antibody, for adults with heavily pretreated relapsed/refractory multiple myeloma, after trials showed a 70% response rate. Also on July 2, 2025, the FDA approved sunvozertinib (Zegfrovy) as the first targeted oral therapy for advanced NSCLC with EGFR exon 20 insertion mutations following chemotherapy. In July…
1 44 45 46

Stock Market Today

  • Palantir Poised for Profit Growth Amid AI Market Caution
    January 22, 2026, 2:14 PM EST. Palantir Technologies (PLTR) shows strong revenue and profit growth, with Q3 revenue up 63% year-over-year to $1.18 billion and operating income more than tripling, reflecting its scalable AI software business model. Despite being valued at over 200 times 2025's expected profits, analysts expect earnings to rise from $0.72 in 2025 to $2.21 by 2029, indicating accelerating profitability. However, the stock trades at a premium with a 112 times trailing sales and 172 times projected 2026 earnings multiple, raising questions about its near-term valuation. Market skepticism about an AI bubble weighs on investor sentiment, but Palantir's solid fundamentals and enterprise customer base position it as a potential 2026 market surprise.
Go toTop